One-year outcomes of patients with the zotarolimus-eluting coronary stent: RESOLUTE International Registry

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F12%3A43906907" target="_blank" >RIV/00216208:11120/12:43906907 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064173:_____/12:43906907

Výsledek na webu

<a href="http://dx.doi.org/10.4244/EIJV7I10A189" target="_blank" >http://dx.doi.org/10.4244/EIJV7I10A189</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.4244/EIJV7I10A189" target="_blank" >10.4244/EIJV7I10A189</a>

Jazyk výsledku

angličtina

Název v původním jazyce

One-year outcomes of patients with the zotarolimus-eluting coronary stent: RESOLUTE International Registry

Popis výsledku v původním jazyce

To provide clinical outcome data from everyday practice for the new generation Resolute zotarolimus-eluting stent (R-ZES). Methods and results: Patients were eligible if placement of >= 1 R-ZES was intended. There were no restrictions on clinical indication, number of treated vessels, and lesion characteristics. The primary endpoint was the adjudicated cumulative 1-year incidence of cardiac death and target vessel myocardial infarction. Twenty-five per cent of the patients were randomly selected for monitoring. We recruited 2,349 patients with 3,147 lesions (1.6 +/- 1.0 steins per patient); 46.0% of patients had acute coronary syndrome, 30.5% were diabetic, and >= 1 complex criterion for stent placement was present in 67.5% of patients. One-year follow-up was complete in 97.9% of patients. The I-year incidence of the primary endpoint was 4.3% (95% CI: 3.5% to 5.2%) and for ARC definite and probable stern thrombosis, 0.9% (0.5% to 1.3%). Clinically driven target lesion revascularisation

Název v anglickém jazyce

One-year outcomes of patients with the zotarolimus-eluting coronary stent: RESOLUTE International Registry

Popis výsledku anglicky

To provide clinical outcome data from everyday practice for the new generation Resolute zotarolimus-eluting stent (R-ZES). Methods and results: Patients were eligible if placement of >= 1 R-ZES was intended. There were no restrictions on clinical indication, number of treated vessels, and lesion characteristics. The primary endpoint was the adjudicated cumulative 1-year incidence of cardiac death and target vessel myocardial infarction. Twenty-five per cent of the patients were randomly selected for monitoring. We recruited 2,349 patients with 3,147 lesions (1.6 +/- 1.0 steins per patient); 46.0% of patients had acute coronary syndrome, 30.5% were diabetic, and >= 1 complex criterion for stent placement was present in 67.5% of patients. One-year follow-up was complete in 97.9% of patients. The I-year incidence of the primary endpoint was 4.3% (95% CI: 3.5% to 5.2%) and for ARC definite and probable stern thrombosis, 0.9% (0.5% to 1.3%). Clinically driven target lesion revascularisation

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

EuroIntervention

ISSN

1774-024X

e-ISSN

—

Svazek periodika

7

Číslo periodika v rámci svazku

10

Stát vydavatele periodika

FR - Francouzská republika

Počet stran výsledku

9

Strana od-do

1181-1188

Kód UT WoS článku

000301616900010

EID výsledku v databázi Scopus

—